Adding ketones to antipsychotics in young adults with first episode psychosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial investigates the clinical and metabolic effects of adding medium-chain triglyceride (MCT) oil-derived ketones to ongoing antipsychotic therapy in adults with first episode psychosis. Participants are adults receiving a stable dose of second- or third-generation antipsychotics and able to consent, funded by Université de Sherbrooke and conducted at Hotel-Dieu CIUSSS de l'Estrie-CHUS in Sherbrooke. The intervention uses MCT oil to provide exogenous ketones, with outcomes focused on psychiatric symptoms and metabolic health. The study builds on existing knowledge that brain energy metabolism may be altered in early psychosis and that antipsychotics carry metabolic risks. Eligibility requires language ability in French or English and exclusion criteria cover pregnancy, diabetes, recent ketogenic interventions, and certain metabolic disorders.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Referred or self-referred to the PEP Clinic of the Estrie region, either as an outpatient or inpatient.
* Currently receiving a second- or third-generation antipsychotic at a stable dose for at least 4 weeks.
* Able to read and communicate in French or English.
* Capable of understanding and signing the informed consent form.

Exclusion Criteria:

* Pregnancy, childbirth within the past 6 months, or breastfeeding.
* any use of MCT oil, ketone salts, or a ketogenic diet within the past year.
* Previous diagnosis of type I or type II diabetes.
* Uncontrolled acute suicidal ideation at the time of inclusion in the PEP clinic.
* Other conditions that may interfere with participation, as determined by the qualified physician.
* Pancreatitis (inflammation of the pancreas) or liver failure.
* Metabolic condition affecting fat metabolism or inherited carnitine deficiency and its related enzymes.
* Porphyria.
* Pyruvate kinase deficiency.
* Neurodevelopmental disorder of unknown etiology or rare genetic disease.

Where it's running

• Hotel-Dieu CIUSSS de l'Estrie-CHUS
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Kevin Zemmour, MD — Université de Sherbrooke
• Study coordinator: Melanie Fortier, M.Sc
• Email: melanie.fortier2@usherbrooke.ca
• Phone: 1-819-821-5206

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• On Track for Wellness: a stepped-wedge program to boost sleep and activity in first-episode psychosis

  This program tests whether using Fitbit trackers, health education, and goal setting helps people with first-episode psychosis sleep better and move more.

  Recruiting University of Illinois Chicago · Chicago, Illinois · NCT07387705

• Add CBD to antipsychotic treatment for first-episode psychosis to see if it helps more than placebo

  This study tests whether adding cannabidiol (CBD) to ongoing antipsychotic treatment helps people with a first episode of psychosis who haven’t fully responded to their first antipsychotic, compared with a placebo.

  Recruiting at 2 sites Phase 3 University of Oxford · Vienna and 16 other locations · NCT06778564

• Digital strategies to improve help-seeking for youth at risk of psychosis

  This study is testing new digital tools to help young people aged 12-29 who are at risk for psychosis find the support they need and start treatment faster.

  Recruiting Columbia University · New York, New York · NCT06774430

• Digital tools to help youth seek care sooner when at risk for psychosis

  This project will test personalized digital messages and online strategies to help people ages 12–29 who screen positive for psychosis risk find and start local care sooner.

  Recruiting Columbia University · New York, New York · NCT06774417

• Biomarkers to predict mood-related versus other courses and treatment response after a first psychotic episode

  This project will test whether recorded interviews, clinical scales, blood markers and brain imaging can help predict who will go on to develop mood-related psychosis (bipolar/depressive with psychotic features) versus other psychoses and who will respond to treatment over two years in people aged 15–30 after their fir

  Recruiting at 4 sites University Hospital, Brest · Angers and 4 other locations · NCT05384392

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.